Related Experiment Video

Updated: Jan 17, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.5K

Biomarkers in Cardiorenal Syndrome: Focus on Type 1

Hiroyuki Naruse1, Hideo Izawa2

  • 1Department of Clinical Pathophysiology, Fujita Health University School of Medical Science, Japan.

Internal Medicine (Tokyo, Japan)
|January 14, 2026
PubMed

Insights

Cardiorenal syndrome (CRS) involves heart and kidney disease interactions. New tubular injury biomarkers show promise for detecting early kidney damage in CRS type 1, improving upon traditional creatinine tests.

Area of Science:

  • Nephrology
  • Cardiology
  • Biomarker Discovery

Background:

  • Cardiorenal syndrome (CRS) is a complex interplay between cardiovascular and renal diseases.
  • Traditional biomarkers like serum creatinine (SCr) and estimated glomerular filtration rate (eGFR) have limitations in early acute kidney injury (AKI) detection in CRS.
  • CRS type 1 involves acute cardiac events precipitating AKI.

Purpose of the Study:

  • To review current renal biomarkers for CRS type 1.
  • To explore the clinical utility of tubular injury biomarkers in identifying subclinical AKI.
  • To address limitations of existing diagnostic criteria for AKI in CRS.

Main Methods:

  • Literature review of renal biomarkers in Cardiorenal Syndrome Type 1.
  • Analysis of diagnostic capabilities of traditional versus novel biomarkers.
  • Evaluation of biomarkers for early detection of acute kidney injury.

Main Results:

  • Serum creatinine and eGFR are often insufficient for early AKI diagnosis in CRS.
  • Tubular injury biomarkers offer improved sensitivity and timeliness for detecting early renal damage.
  • Subclinical AKI can be identified using these novel biomarkers.

Conclusions:

  • Novel renal biomarkers, particularly those indicating tubular injury, are crucial for early AKI detection in CRS type 1.
  • These biomarkers can overcome the limitations of SCr and eGFR, enabling timely intervention.
  • Further clinical application of these biomarkers can improve patient outcomes in CRS.

Keywords:
acute kidney injurybiomarkerscardiorenal syndrome type 1subclinical acute kidney injury

More Related Videos

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.5K
Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches06:51

Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches

Published on: September 5, 2025

533

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
540
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
800
Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
364
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
260
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
730
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936